AYTU Aytu BioPharma announced today that the FDA has granted Fast Track designation to AR101, a protein kinase inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome.
After the bullish news, AYTU stock hit the all time low level.
52 Week Range 0.76 - 7.20
LADENBURG THALM has a price target of $14.50 for the stock.
I think a reversal is imminent.
My price target is $5.25.
Looking forward to read your opinion about it.
After the bullish news, AYTU stock hit the all time low level.
52 Week Range 0.76 - 7.20
LADENBURG THALM has a price target of $14.50 for the stock.
I think a reversal is imminent.
My price target is $5.25.
Looking forward to read your opinion about it.
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880